LianBio (LIAN)

NASDAQ: LIAN · IEX Real-Time Price · USD
1.37
-0.04 (-2.84%)
At close: Dec 7, 2022 3:59 PM
1.39
+0.02 (1.46%)
After-hours: Dec 7, 2022 4:00 PM EST
-2.84%
Market Cap 152.78M
Revenue (ttm) n/a
Net Income (ttm) -113.21M
Shares Out 108.35M
EPS (ttm) -2.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 90,039
Open 1.41
Previous Close 1.41
Day's Range 1.32 - 1.45
52-Week Range 1.07 - 10.36
Beta n/a
Analysts Buy
Price Target 9.92 (+624.1%)
Earnings Date Dec 8, 2022

About LIAN

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-li... [Read more]

Industry Biotechnology
IPO Date Nov 1, 2021
Employees 107
Stock Exchange NASDAQ
Ticker Symbol LIAN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for LIAN stock is "Buy." The 12-month stock price forecast is 9.92, which is an increase of 624.09% from the latest price.

Price Target
$9.92
(624.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...

3 weeks ago - GlobeNewsWire

LianBio to Participate in Upcoming Investor and Industry Events

SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...

3 weeks ago - GlobeNewsWire

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

SHANGHAI, China and PRINCETON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...

4 weeks ago - GlobeNewsWire

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

•   LIBRA trial designed to support registration in China •   Topline results expected in the fourth quarter of 2023

1 month ago - GlobeNewsWire

NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the...

PARIS & CAMBRIDGE, Mass. & SHANGHAI, China & PRINCETON, N.J.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), a late-stage clinical biotechnology compan...

Other symbols: NBTX
3 months ago - Business Wire

LianBio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SHANGHAI, China and PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...

3 months ago - GlobeNewsWire

LianBio to Participate in June Investor Events

SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...

6 months ago - GlobeNewsWire

LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update

SHANGHAI, China and PRINCETON, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asia...

6 months ago - GlobeNewsWire

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers

6 months ago - GlobeNewsWire

LianBio to Participate in the Bank of America Securities 2022 Healthcare Conference

SHANGHAI, China and PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) --  LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...

7 months ago - GlobeNewsWire

LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Tre...

LianBio Holds Development and Commercialization Rights to TP-03 in Greater China LianBio Holds Development and Commercialization Rights to TP-03 in Greater China

7 months ago - GlobeNewsWire

U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York...

LianBio to Continue Development of Camzyos in China and Other Asian Territories LianBio to Continue Development of Camzyos in China and Other Asian Territories

7 months ago - GlobeNewsWire

LianBio Announces Formation of Scientific Advisory Board

Scientific Advisory Board strengthens LianBio's mission of bringing novel therapeutics to Greater China and Asia Scientific Advisory Board strengthens LianBio's mission of bringing novel therapeutics to...

7 months ago - GlobeNewsWire

LianBio's Partner ReViral Enters into Acquisition Agreement with Pfizer

Acquisition builds on LianBio's existing partnership with Pfizer to bring novel therapeutics to Greater China Acquisition builds on LianBio's existing partnership with Pfizer to bring novel therapeutics...

8 months ago - GlobeNewsWire

LianBio Appoints Wei Wei Chen to Board of Directors

SHANGHAI and PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian mar...

8 months ago - GlobeNewsWire

LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing

8 months ago - GlobeNewsWire

LianBio Issues Statement Regarding the HFCAA

Company's principal auditor is located in the United States and is currently inspected by the PCAOB Company's principal auditor is located in the United States and is currently inspected by the PCAOB

8 months ago - GlobeNewsWire

LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China

SHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian mark...

9 months ago - GlobeNewsWire

LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients w...

EXPLORER-CN trial designed to support regulatory filing in Mainland China EXPLORER-CN trial designed to support regulatory filing in Mainland China

10 months ago - GlobeNewsWire

LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma i...

SHANGHAI, China and PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asi...

11 months ago - GlobeNewsWire

LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Initiated and completed dosing in pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers

11 months ago - GlobeNewsWire

LianBio stock opens below the IPO price, reversing early indications of a rally

LianBio LIAN, -11.38% got off to a rocky start as a public company, as the first trade of the shares of biotechnology company with operations in the U.S. and China was 3.1% below the initial public offe...

1 year ago - Market Watch

LianBio to go public as IPO prices in middle of expected range, as the biotech was valued at about $1.7 billion

LianBio LIAN, -2.22% is set to go public Monday, after the biotechnology company with operations in the U.S. and China said its initial public offering priced at $16 a share, in the middle of the expect...

1 year ago - Market Watch

LianBio Announces Pricing of Initial Public Offering

SHANGHAI, China and PRINCETON, N.J., Oct. 31, 2021 (GLOBE NEWSWIRE) -- LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, tod...

1 year ago - GlobeNewsWire